Lise Lotte Gluud

Medicine & Life Sciences

1. Meta-Analysis 100%
2. Fibrosis 99%
3. Systematic Reviews 84%
4. Non-alcoholic Fatty Liver Disease 81%
5. Hepatic Encephalopathy 69%
6. Randomized Controlled Trials 45%
7. Type 2 Diabetes Mellitus 44%
8. Liver 43%
9. Liver Diseases 35%
10. Mortality 35%
11. Acute Necrotizing Pancreatitis 31%
12. Placebos 30%
13. Confidence Intervals 29%
14. Acute-On-Chronic Liver Failure 27%
15. Hepatorenal Syndrome 26%
16. Chronic Hepatitis C 26%
17. Glucagon 24%
18. Glucose 23%
19. Ascites 23%
20. Rifaximin 23%
21. Therapeutics 22%
22. Fatty Liver 21%
23. Hemorrhage 21%
24. Ribavirin 20%
25. Umbilical Hernia 19%
26. Disaccharides 19%
27. Odds Ratio 18%
28. Glucagon-Like Peptide 1 18%
29. Transjugular Intrahepatic Portasystemic Shunt 17%
30. Liver Cirrhosis 17%
31. Glucagon-Like Peptide-1 Receptor 17%
32. Herniorrhaphy 15%
33. Pancreatitis 15%
34. Cohort Studies 15%
35. Terlipressin 15%
36. Esophageal and Gastric Varices 14%
37. Inflammatory Bowel Diseases 13%
38. Lactulose 12%
39. Ammonia 12%
40. Obesity 12%
41. Liver Transplantation 12%
42. Gestational Diabetes 12%
43. Observational Studies 12%
44. Interferons 11%
45. Crohn Disease 11%
46. Branched Chain Amino Acids 11%
47. Fecal Microbiota Transplantation 11%
48. Necrosis 10%
49. Sodium-Glucose Transporter 2 Inhibitors 10%
50. Weight Loss 10%